Vir Biotechnology (VIR) Debt to Equity (2019 - 2025)

Name: Vir Biotechnology (VIR) Debt to Equity (2019 - 2025) | Business Quant
Creator: Business Quant

Vir Biotechnology recorded quarterly Debt to Equity of $0.02 in Q1 2025, up 20.09% quarter-over-quarter from $0.01 in Q4 2024.

Vir Biotechnology's Debt to Equity history runs 5 years deep, the most recent figure standing at $0.02 for Q1 2025.

In Q1 2025, Debt to Equity changed N/A year-over-year to $0.02; the TTM figure through Mar 2025 stood at $0.02 (changed N/A YoY), while the FY2024 annual figure was $0.01, changed N/A from the prior year.
Debt to Equity came in at $0.02 for Q1 2025 at Vir Biotechnology, up from $0.01 in the prior quarter.
In the past five years, Debt to Equity ranged from a high of $0.08 in Q3 2021 to a low of $0.01 in Q4 2024.
A 3-year average of $0.04 and a median of $0.04 in 2021 frame the typical range for Debt to Equity.
On a YoY basis, Debt to Equity climbed as much as 326.24% in 2021 and fell as far as 33.24% in 2021.
Vir Biotechnology's Debt to Equity stood at $0.08 in 2021, then tumbled by 82.14% to $0.01 in 2024, then climbed by 20.09% to $0.02 in 2025.
According to Business Quant data, Debt to Equity over the past three periods registered $0.02, $0.01, and $0.08 for Q1 2025, Q4 2024, and Q3 2021 respectively.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt/Equity (Qtr)
1	Quantum Biopharma	961,148.99 Bn	961,148.98 Bn	-	-
2	Alterity Therapeutics	744,933.29 Bn	744,933.26 Bn	-	-
3	Legend Biotech	2,540.00 Bn	2,539.71 Bn	242.10 Mn	-
4	Nanobiotix	2,199.85 Bn	2,199.78 Bn	-	-
5	Akari Therapeutics	1,635.88 Bn	1,635.88 Bn	-	-
6	Vertex Pharmaceuticals	111.32 Bn	104.07 Bn	2.59 Bn	-
7	Evaxion A	62.56 Bn	62.54 Bn	-	-
8	Regeneron Pharmaceuticals	62.55 Bn	53.79 Bn	3.31 Bn	0.06
9	Alnylam Pharmaceuticals	39.57 Bn	36.56 Bn	959.66 Mn	-
10	Vir Biotechnology	1.33 Bn	1.33 Bn	-	-

Download Data 🔒